Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Tevogen Bio Holdings Inc. - Common Stock
(NQ:
TVGN
)
1.000
-0.070 (-6.54%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 3, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Tevogen Bio Holdings Inc. - Common Stock
< Previous
1
2
3
Next >
Tevogen Bio CEO Named to NJBIZ 2025 Health Care Power List as Company Advances Commercialization; Reaffirms Timeframe on Previously Announced Forecast
March 26, 2025
From
Tevogen Bio Inc
Via
GlobeNewswire
Tevogen Bio Appoints David E. Banko as Global Head of Government Affairs and Patient Access, Advances Commercialization Plan
March 25, 2025
From
Tevogen Bio Inc
Via
GlobeNewswire
Tevogen Bio Announces Unique T Cell Vaccine Under Development and Files Patent with the USPTO
March 10, 2025
From
Tevogen Bio Inc
Via
GlobeNewswire
Tevogen Bio’s CIO & Head of Tevogen.AI, Mittul Mehta, Featured Speaker at Proskauer’s AI Discussion Panel
March 07, 2025
From
Tevogen Bio Inc
Via
GlobeNewswire
Tevogen Bio to Receive $8 Million of Non-Dilutive Grant Funding, Reiterates Efficient Operations
March 03, 2025
From
Tevogen Bio Inc
Via
GlobeNewswire
Tevogen Bio Founder and CEO Dr. Ryan Saadi Named to 2025 NJBIZ Power 100, Celebrating Innovation and Leadership in Accessible T Cell Therapy
February 28, 2025
From
Tevogen Bio Inc
Via
GlobeNewswire
Tevogen Bio’s First Trading Year Efficiency: 600% Higher Market Cap Per Team Member, 79% Insider-Owned
February 21, 2025
From
Tevogen Bio Inc
Via
GlobeNewswire
Tevogen Bio CEO Reinforces Commitment to Retention of Equity Capital and Long-Term Vision
February 14, 2025
From
Tevogen Bio Inc
Via
GlobeNewswire
Tevogen Bio Shares 2024 Financing Activity on One Year Anniversary of Becoming a Publicly Listed Company; Highlights Operational Efficiency
February 14, 2025
From
Tevogen Bio Inc
Via
GlobeNewswire
Tevogen Bio CEO Addresses Short Selling and Its Potential Impact on the Nation’s Health and Prosperity
February 14, 2025
From
Tevogen Bio Inc
Via
GlobeNewswire
Tevogen Bio CEO Congratulates RFK Jr. on His Confirmation as Secretary of the HHS; Echoes Commitment to Innovation and Affordability for Americans
February 13, 2025
From
Tevogen Bio Inc
Via
GlobeNewswire
Tevogen Bio's Business Model Addresses Biopharma Industry Challenges with Cost-Efficient Innovation
February 10, 2025
From
Tevogen Bio Inc
Via
GlobeNewswire
Tevogen Bio Meets BARDA TechWatch Team, Highlighting ExacTcell™ Technology’s Potential as a Scalable Medical Countermeasure
February 07, 2025
From
Tevogen Bio Inc
Via
GlobeNewswire
Tevogen Bio Enters Agreement to Receive Up To $10 Million of Non-Dilutive Grant Funding
January 28, 2025
From
Tevogen Bio Inc
Via
GlobeNewswire
Tevogen Bio CEO Congratulates Lynne Patton on Being Appointed Deputy Assistant to the President and Director of Minority Outreach
January 27, 2025
From
Tevogen Bio Inc
Via
GlobeNewswire
Tevogen Bio Broadens Relationship with Microsoft to Deepen Artificial Intelligence Collaboration and Develop PredicTcell Technology on Azure
January 24, 2025
From
Tevogen Bio Inc
Via
GlobeNewswire
Tevogen Bio to Host Panel Discussions “AI In Biopharma: Next Frontier of Medical Innovation” and “Pioneering the Economics of Health: Balancing Access and Outcomes” During J.P. Morgan Healthcare Conference
December 26, 2024
From
Tevogen Bio Inc
Via
GlobeNewswire
Tevogen Bio Highlights the Future of AI-Driven Drug Development in Fireside Chat with Microsoft During the J.P. Morgan Healthcare Conference
January 23, 2025
From
Tevogen Bio Inc
Via
GlobeNewswire
Tevogen Bio to Host Panel "AI In Biopharma: Next Frontier of Medical Innovation" During the 43rd Annual J.P. Morgan Healthcare Conference
December 23, 2024
From
Tevogen Bio Inc
Via
GlobeNewswire
Tevogen Bio Strengthens Robust IP Portfolio With Filing of Predictive AI Patent, With the Goal to Establish a Blueprint to Unlock the Full Potential of T Cell Therapies and Accelerate AI Integration to Advance Its Bold Growth Agenda
December 19, 2024
From
Tevogen Bio Inc
Via
GlobeNewswire
Tevogen Bio to Host Panel “Pioneering the Economics of Health: Balancing Access and Outcomes” During the 43rd Annual J.P. Morgan Healthcare Conference
December 17, 2024
From
Tevogen Bio Inc
Via
GlobeNewswire
Tevogen Bio to Attend the 43rd Annual J.P. Morgan Healthcare Conference
December 10, 2024
From
Tevogen Bio Inc
Via
GlobeNewswire
Dr. Ryan Saadi Commends Individuals Who Dedicate Time to Public Service, and Congratulates Mayor Victor Sordillo on His Induction Into the NJ League of Municipalities Hall of Fame
December 05, 2024
From
Tevogen Bio Inc
Via
GlobeNewswire
Tevogen Bio Prepares Organizational Readiness to Support Company’s Growth Strategy
November 26, 2024
From
Tevogen Bio Inc
Via
GlobeNewswire
Tevogen Bio CEO Reflects on Public Support, Reaffirms Preserving Shareholder Value Remains His Priority, and Reinforces Options Including a Potential Share Buyback to Support Company Value
November 21, 2024
From
Tevogen Bio Inc
Via
GlobeNewswire
Tevogen Bio Reports Third Quarter 2024 Financial Results; Highlights Significantly Improved Financial Position, Unreported Asset Value on Balance Sheets, Efficient Business Model
November 19, 2024
From
Tevogen Bio Inc
Via
GlobeNewswire
UPDATE - Tevogen Founder Reflects on Importance of Preserving Shareholder Value While Navigating Growth as it Prepares to File Quarterly Financials
November 14, 2024
From
Tevogen Bio Inc
Via
GlobeNewswire
Tevogen Founder Reflects on Importance of Preserving Shareholder Value While Navigating Growth as it Prepares to File Quarterly Financials
November 14, 2024
From
Tevogen Bio Inc
Via
GlobeNewswire
Tevogen Bio Nears Finalization of Agreement to Enhance R&D and Manufacturing Capabilities; $36 Million Line of Credit Available for Continued Operations
November 08, 2024
From
Tevogen Bio Inc
Via
GlobeNewswire
Tevogen Bio CEO Dr. Ryan Saadi Expresses Gratitude for Prestigious ROI-NJ Recognition, Highlighting Company’s Novel Business Model as Key to Sustainable Success through Patient Affordability
November 05, 2024
From
Tevogen Bio Inc
Via
GlobeNewswire
< Previous
1
2
3
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.